Stage IVA Colorectal Cancer Clinical Trial
Official title:
A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients
This phase I trial studies the side effects and the best dose of irinotecan hydrochloride, based on a genetic test, when given in combination with fluorouracil, leucovorin calcium, and cetuximab as first-line therapy in treating patients with an abnormal gene called RAS wild-type that has spread to other parts of the body (metastatic). Patients may also have a gene called uridine diphosphate glucuronosyltransferase (UGT1A1) that may interfere with the way irinotecan hydrochloride is absorbed by the body and may not be able to tolerate it. Determining the presence of this gene may help determine the best dose of irinotecan hydrochloride when given with fluorouracil and leucovorin calcium (FOLFIRI). Combination chemotherapy, such as FOLFIRI, works in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cetuximab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving FOLFIRI together with cetuximab may be a better treatment for patients with colorectal cancer.
PRIMARY OBJECTIVES:
I. To define the maximum tolerated dose (MTD), the dose limiting toxicity (DLT) and the
phase II recommended dosage of irinotecan (irinotecan hydrochloride) administered in the
FOLFIRI regimen plus cetuximab in metastatic colorectal cancer (mCRC) patients with *1/*1
and *1/*28 uridine diphosphate glucuronosyltransferase (UGT1A1) genotype treated as first
line chemotherapy.
SECONDARY OBJECTIVE:
To estimate the response rate, progression-free survival (PFS) and metastasectomy (with
curative intent) rate in the overall patient population (both genotype cohorts).
OTHER OBJECTIVES:
I. To evaluate the variability of irinotecan pharmacokinetics, in combination with
cetuximab, in patients with *1/*1 and *1/*28 genotype and the effect of the pharmacokinetic
profile on toxicity and response rate.
II. To evaluate the pharmacokinetic profile of irinotecan and its major metabolites in the
absence and the presence of cetuximab administration, in order to define the effect of the
chimeric monoclonal antibody on irinotecan pharmacokinetics.
OUTLINE: This is a dose-escalation study of irinotecan hydrochloride in patients with
UGT1A1.
Patients receive irinotecan hydrochloride intravenously (IV) over 1-2 hours, fluorouracil IV
continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also
receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all
subsequent courses. Courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
Withdrawn |
NCT02413853 -
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03005002 -
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
|
Phase 1 | |
Completed |
NCT03095781 -
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
Completed |
NCT02511821 -
Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery
|
N/A | |
Recruiting |
NCT03368963 -
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03800602 -
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
|
Phase 2 | |
Terminated |
NCT02650635 -
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
|
Phase 1 | |
Terminated |
NCT02508077 -
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Completed |
NCT03373188 -
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02713373 -
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT04044430 -
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02489422 -
Programs To Support You During Chemotherapy
|
N/A | |
Completed |
NCT02837263 -
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT03087591 -
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
|
Phase 1 | |
Active, not recruiting |
NCT03275974 -
Glutamine PET Imaging Colorectal Cancer
|
Phase 1 |